Aptamer licences Optimer binders for swine vaccines

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has entered into a global licensing agreement with the University of Glasgow for the commercial use of a developed panel of Optimer binders as vaccine adjuvants in the swine health sector.

Successful project delivery of Optimer binders with proven function as vaccine adjuvants

Aptamer to receive 10% royalties on downstream sales of any Optimer-containing vaccines

Under the terms of the agreement, the University of Glasgow receives exclusive rights to a panel of Optimers for use as adjuvants in vaccine development. The University will lead product development, with commercialisation anticipated within the next 12 months. Aptamer will receive a 10% royalty on all future revenues from any vaccines incorporating the licensed Optimers, creating a scalable, global, non-dilutive revenue stream.

This partnership provides Aptamer access to the $1.75 billion global swine vaccine market (2024)1, an industry experiencing sustained demand for improved animal health solutions. The licensed Optimers, originally developed under a fee-for-service model, have demonstrated strong immune-enhancing capabilities in preclinical studies led by the University of Glasgow, suggesting significant potential for their use in improving immune response and health outcomes in pigs, an area of major interest within the global veterinary and agricultural markets.

Dr Arron Tolley, Chief Executive Officer of Aptamer, said: “This licensing deal represents an important milestone in the commercialisation of our Optimer technology. It demonstrates our ability to deliver high-value solutions across diverse sectors and builds on our strategic focus of monetising Optimer-based assets beyond our core focus in human health. With growing demand for advanced animal health solutions, this partnership creates a global pathway to recurring revenues while validating the robustness and versatility of our Optimer platform.

This agreement reinforces Aptamer’s broader commercial strategy of leveraging its proprietary platform across multiple verticals, including targeted drug delivery for human therapeutics, diagnostics, personal care, research reagents, and now veterinary vaccines, to generate long-term shareholder value.”

1. Grand View Research. Swine Vaccines Market Size, Share & Trends Analysis Report By Product (Inactivated, Modified/Attenuated Live), By Type (Pseudorabies, Porcine Circovirus Type 2), By Route Of Administration, By Region, And Segment Forecasts, 2025 – 2030. Report ID: GVR-4-68039-728-0

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

    Aptamer Group raises £2.0 million in share placing

    Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

    Aptamer Group raises £2m to fund growth

    Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

    Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

    Aptamer expands odour control collaboration with Unilever

    Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.

      Search

      Search